https://endpts.com/novartis-to-buy-morphosys-for-2-9b-after-20-years-of-creating-antibodies-with-the-german-biotech/
Look at this article and see the amount of money pharma companies are throwing around to get hold of different drugs and therapies. The valuation mesoblast is trading is peanuts. I think the management should do whatever it takes to push Rem-L over the line as that will increase the valuation of the company by multiple folds. Hopefully the team at mesoblast understands this and takes the advantage of the current biotech run.
https://endpts.com/novartis-to-buy-morphosys-for-2-9b-after-20-ye...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.020(1.73%) |
Mkt cap ! $1.341B | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.21 | $1.17 | $16.67M | 14.04M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 54704 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.19 |
Change
0.020 ( 3.40 %) |
||||
| Open | High | Low | Volume | ||
| $1.21 | $1.21 | $1.17 | 2927691 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| MSB (ASX) Chart |